AM Press ReleasesBioprinting

Single-cell bioprinting platform Biopixlar enables detailed biological tissues

With more than 95% cell viability

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

In a scientific article published in Scientific Reports, researchers at Fluicell AB in collaboration with Cellectricon AB and Karolinska Institutet, demonstrated the generation of complex 3D biological tissues using the single-cell bioprinting platform Biopixlar.  The paper presents new and exciting possibilities for Biopixlar-printed tissues to be used in drug testing and disease modeling.

Establishing biologically relevant in vitro systems for disease modeling has, for a long time, been a challenge due to the lack of micro-environmental control necessary to replicate human tissue and organ histology. In the new study, the team of scientists shows how Biopixlar allows researchers to position individual cells in complex patterns enabling them to create biological tissues with the same high precision as in human tissues. The biological relevance created by Biopixlar’s high-resolution bioprinting technology allow created tissues to be used for drug testing and disease modeling.

“Because of its versatility, Biopixlar offers many new opportunities for researchers. With it, we can print everything from tissues such as tissue types, including skin, liver, and a variety of cancer models using human histology as a template. And importantly, more than 95% of the cells that you print stay alive,” commented Dr. Tatsiana Lobovkina, CSO of Fluicell.

The ability to positions cells right where and when you want them, not only allows researchers to create in vitro biological tissues but also opens up new possibilities for applications within personalized medicine and advanced therapies.

“Being able to directly control the local environment around cells is very important for directing stem cell development, a key aspect in tissue generation for regenerative or therapeutic applications,” added Dr. Gavin Jeffries, CTO of Fluicell, “we believe that this will allow Biopixlar to be a very valuable tool, not just for research, but also for development on new therapies,

Prof. Owe Orwar, Karolinska Institutet and Fluicell board member, added: “Biopixlar is a game-changing technology and sets a new standard for facile, true-to-the-original, high-resolution bioprinting. It has all the key attributes to become a highly important player in translational drug discovery and therapeutic development,

The work presented in the article 3D micro-organisation printing of mammalian cells to generate biological tissues, published in Scientific Reports, is a collaboration between researchers from Fluicell AB, Cellectricon AB and Karolinska Institutet. Scientific Reports is an online open-access journal published by Nature Research.

Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Victor Anusci

Victor does not really exist. He is a pseudonym for several writers in the 3D Printing Media Network team. As a pseudonym, Victor has also had a fascinating made-up life story, living as a digital (and virtual) nomad to cover the global AM industry. He has always worked extra-hard whenever he was needed to create unique content. However, lately, as our editorial team has grown, he is mostly taking care of publishing press releases.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.